Articles>> Volume 5 Issue 1, 2021

COVID-19 and risk of cardiomyocyte injury: The prevailing scenario
Marwa S. Al-Niemi, Nawar R. Hussain, Hayder M. Al-Kuraishy and Ali I. Al-Gareeb2
Curr Med Drug Res 5 (1): Art. ID 211 (2021)
The novel coronavirus which is also called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is responsible for COVID-19 (coronavirus disease 2019). SARS-CoV-2 is known to cause substantial pulmonary disease, including pneumonia and acute respiratory distress syndrome (ARDS), clinicians have observed many extra-pulmonary manifestations of COVID-19. SARS‐CoV‐2 infection is associated with a variety of pro‐inflammatory mediators that may play important roles in the pathophysiology of cardiac and arrhythmic complications. Systemic inflammatory response syndrome (cytokine storm) is another putative mechanism of myocardial injury. In addition to lung damage, there may be significant cardiac involvement in patients with COVID-19, which is responsible for worsening the clinical condition of the host. The main cardiac manifestations can be oedema, pericarditis, cardiac fibrosis, myocarditis, impairment of contractile function and cardiac electrophysiology. The cardiac status of patients with ongoing SARS-CoV-2 infection of surviving patients in convalescence period should be carefully monitored.

Related Article

The potential role of Bromhexine in the management of COVID-19: Decipher and a real game-changer
Hayder M. Al-Kuraishy, Marwa S. Al-Niemi, Nawar R. Hussain, Ali I. Al-Gareeb and Claire Lugnier
Curr Med Drug Res 5 (1): Art. ID 212 (2021)

Current and future role of immobilized enzymes in medical field
Mohammad Rafiq Khan
Curr Med Drug Res 5 (1): Art. ID 213 (2021)

Spatial mapping and enshrined capacity: Assessment of COVID-19 servicing Indian hospitals
N. Ravichandran, S. Shivangi and B. Rakesh
Curr Med Drug Res 5 (1): Art. ID 214 (2021)

Elucidation of the origin of autoimmune diseases via computational multiscale mechanobiology and extracellular matrix remodeling: theories and phenomenon of immunodominance
Rajiv Kumar
Curr Med Drug Res 5 (1): Art. ID 215 (2021)